ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $583,044 | -12.6% | 29,065 | +22.9% | 0.00% | 0.0% |
| Q2 2023 | $667,054 | +71.2% | 23,646 | +4.4% | 0.00% | +33.3% |
| Q1 2023 | $389,735 | -12.9% | 22,659 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $447,269 | -7.4% | 22,208 | -0.4% | 0.00% | -25.0% |
| Q3 2022 | $483,000 | -4.4% | 22,289 | +24.0% | 0.00% | +33.3% |
| Q2 2022 | $505,000 | -39.5% | 17,982 | -0.7% | 0.00% | -40.0% |
| Q1 2022 | $835,000 | -48.7% | 18,103 | -6.6% | 0.01% | -37.5% |
| Q4 2021 | $1,629,000 | +24.4% | 19,379 | -1.4% | 0.01% | +14.3% |
| Q3 2021 | $1,309,000 | +32.1% | 19,649 | +5.5% | 0.01% | +133.3% |
| Q2 2021 | $991,000 | +36.3% | 18,630 | +11.2% | 0.00% | 0.0% |
| Q1 2021 | $727,000 | -16.2% | 16,755 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $868,000 | +285.8% | 16,711 | +142.5% | 0.00% | +200.0% |
| Q3 2020 | $225,000 | -26.0% | 6,892 | +9.0% | 0.00% | 0.0% |
| Q2 2020 | $304,000 | – | 6,323 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |